Long-Term Survival of Patients With Hiv-Related Systemic Non-Hodgkin's Lymphomas

Abstract

long-term survival and possibly cure can be obtained in some patients with HIV-NHL, in particular in those with a better PS and a less advanced immune dysfunction. In fact some of these patients are alive without evidence of disease 4 to 7 years after therapy, and others died of causes related to underlying HIV infection, in particular opportunistic infections, rather than relapse of NHL.

Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus

“…17 The pathologic type of NHL described as prognostic in non-HIV-infected patients 4 was not found to be a significant prognostic factor in the current study, as has been reported previously among HIV-infected patients. 13,16,18 Other authors have presented results close those of the current study, 28,29 although these used other classifications: (Kiel 30 or REAL [Revised European-American Lymphoma 31 ]) actually recommended in the field of NHL. 32 We chose the Working Formulation to allow the classification of all those patients whose diagnosis was established over the past 12 years, and who could not be reevaluated.…”

“…10 The majority of the literature confirms this poor prognosis, with a median survival time estimated between 3.9 -18 months. 1,4 -6,11-17 Some studies examined prognostic factors of NHL survival, 13,15,17,18 but to our knowledge none could determine the impact of highly active antiretroviral therapy (HAART) in a prospective cohort adjusted for known predictive factors. Therefore, the objective of the current study was to examine determinants of survival after a diagnosis of noncerebral NHL in a prospective multirisk cohort including HIV positive patients of both genders treated with a combination of ARV according to evolving standards in France.…”

Prolonged survival with HIV-1 related nasal non-Hodgkin's lymphoma

“…Following treatment of extranodal NHL, complete remission for 2 years is often considered a cure in the general population 3 . In HIV, poor prognostic factors for survival in this group include a low CD4 count (<100/mm 3 ) often with a prior AIDS-de® ning illness, the presence of`B' symptoms suggesting dissemination, and a low performance status at diagnosis 4 ; the average survival following diagnosis has been variously reported as 5± 8 months, and 3.5 months (range 3± 27 months) for sinonasal disease 3± 5 .…”

Safety of allogeneic Epstein–Barr virus (EBV)‐specific cytotoxic T lymphocytes for patients with refractory EBV‐related lymphoma

“…Similar to transplant recipients, EBV also induces malignant B‐cell lymphomas in AIDS patients, although not all the tumours have a Latency III phenotype (Shibata et al , 1991). Systemic multi‐agent chemotherapy can result in remission of disease, but is associated with increased morbidity (Levine et al , 1991; Tirelli et al , 1996). Studies have demonstrated that certain characteristics define a group of AIDS‐related non‐Hodgkin's lymphoma (NHL) patients at high risk of doing poorly, with or without current lymphoma therapies (Levine et al , 1991; Straus et al , 1998).…”